- Home
- XNCR
XNCR
Xencor Inc.
as of 03-06-2026 3:55pm EST
$11.30
+$0.14
+1.25%
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 881.9M | IPO Year: | 2013 |
| Target Price: | $22.89 | AVG Volume (30 days): | 560.6K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.24 | EPS Growth: | 65.36 |
| 52 Week Low/High: | $6.92 - $18.69 | Next Earning Date: | N/A |
| Revenue: | $125,576,000 | Revenue Growth: | 13.65% |
| Revenue Growth (this year): | -1.47% | Revenue Growth (next year): | 6.52% |
| P/E Ratio: | -8.96 | Index: | N/A |
| Free Cash Flow: | -138267000.0 | FCF Growth: | N/A |
AI-Powered XNCR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 84.52%
84.52%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Xencor Inc. (XNCR)
Dahiyat Bassil I
Sell
PRESIDENT & CEO
XNCR Mar 3, 2026
Avg Cost/Share
$11.90
Shares
6,758
Total Value
$80,387.09
Owned After
567,792
SEC Form 4
Desjarlais John R
Sell
SR. VICE PRESIDENT & CSO
XNCR Mar 3, 2026
Avg Cost/Share
$11.90
Shares
2,663
Total Value
$31,676.65
Owned After
270,451
SEC Form 4
Eckert Celia
Sell
SVP, GENERAL COUNSEL
XNCR Mar 3, 2026
Avg Cost/Share
$11.90
Shares
1,492
Total Value
$17,747.49
Owned After
81,929
SEC Form 4
Dahiyat Bassil I
Sell
PRESIDENT & CEO
XNCR Dec 19, 2025
Avg Cost/Share
$15.71
Shares
114,377
Total Value
$1,796,862.67
Owned After
567,792
SEC Form 4
Desjarlais John R
Sell
SR. VICE PRESIDENT & CSO
XNCR Dec 19, 2025
Avg Cost/Share
$15.72
Shares
73,367
Total Value
$1,153,329.24
Owned After
270,451
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Mar 3, 2026 | Sell | $11.90 | 6,758 | $80,387.09 | 567,792 | |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Mar 3, 2026 | Sell | $11.90 | 2,663 | $31,676.65 | 270,451 | |
| Eckert Celia | XNCR | SVP, GENERAL COUNSEL | Mar 3, 2026 | Sell | $11.90 | 1,492 | $17,747.49 | 81,929 | |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Dec 19, 2025 | Sell | $15.71 | 114,377 | $1,796,862.67 | 567,792 | |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Dec 19, 2025 | Sell | $15.72 | 73,367 | $1,153,329.24 | 270,451 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 25, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 25, 2026 · 100% conf.
AI Prediction SELL
1D
-2.07%
$11.73
Act: +13.11%
5D
-6.24%
$11.23
Act: +6.34%
20D
-5.65%
$11.30
Price: $11.98 Prob +5D: 0% AUC: 1.000
0001326732-26-000014
xncr-20260225FALSE000132673200013267322026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026
XENCOR, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3618220-1622502
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
465 North Halstead Street, Suite 200 Pasadena, California 91107
(Address of principal executive offices)(Zip Code)
(626) 305-5900 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareXNCRNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition. On February 25, 2026, Xencor, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in “Item 2.02. Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description 99.1Press Release issued by Xencor, Inc. on February 25, 2026.
104Cover Page Interactive Data File (formatted as inline XBRL).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 25, 2026
XENCOR, INC.
By:/s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary
3
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 8, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 8, 2026 · 100% conf.
AI Prediction SELL
1D
-2.07%
$11.73
Act: +13.11%
5D
-6.24%
$11.23
Act: +6.34%
20D
-5.65%
$11.30
Price: $11.98 Prob +5D: 0% AUC: 1.000
0001326732-26-000002
xncr-20260108FALSE000132673200013267322026-01-082026-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026
XENCOR, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3618220-1622502
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number)
465 North Halstead Street, Suite 200 Pasadena, California 91107
(Address of Principal Executive Offices)(Zip Code)
(626) 305-5900 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.01 per shareXNCRNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
Xencor, Inc. (the “Company”) preliminarily estimates that its cash, cash equivalents and marketable debt securities as of December 31, 2025 were approximately $611 million, compared to $706.7 million as of December 31, 2024. Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations through 2028.
These preliminary estimates are not a comprehensive statement of the Company’s financial results for the year ended December 31, 2025 and have not been audited, reviewed, or compiled by its independent registered public accounting firm. The Company’s actual cash, cash equivalents and marketable debt securities as of December 31, 2025 may differ from these estimates due to the completion of the Company’s year-end closing and auditing procedures.
The information furnished under this Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description 99.1Press release issued by Xencor, Inc. on January 8, 2026.
104Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2026
XENCOR, INC.
By:/s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001326732-25-000086
xncr-20251105FALSE000132673200013267322025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
XENCOR, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3618220-1622502
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
465 North Halstead Street, Suite 200 Pasadena, California 91107
(Address of principal executive offices)(Zip Code)
(626) 305-5900 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareXNCRNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition. On November 5, 2025, Xencor, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in “Item 2.02. Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits.
Exhibit No.Description 99.1Press Release issued by Xencor, Inc. on November 5, 2025.
104Cover Page Interactive Data File (formatted as inline XBRL).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025
XENCOR, INC.
By:/s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary
3
Latest Xencor Inc. News
XNCR Breaking Stock News: Dive into XNCR Ticker-Specific Updates for Smart Investing
Compare XNCR vs Leading Stocks
See how XNCR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XNCR Xencor Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.